Strategy of management of patients with non-rheumatic valvular heart diseases (before and after surgery)
- Autores: Gendlin G.Y.1, Yemelina Y.I.1, Nikitin I.I.1
-
Afiliações:
- N.I. Pirogov Russian national research medical university
- Edição: Nº 2 (2017)
- Páginas: 34-42
- Seção: Articles
- URL: https://journals.eco-vector.com/2412-4036/article/view/277633
- ID: 277633
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Timely cardiosurgical treatment of patients with valvular heart diseases prolongs their life and improves its quality; late diagnosis leads to decompensation, and, sometimes, to the impossibility of a radical correction of the defect. The traditional association of valvular heart disease with rheumatic fever, and now with the valve "degeneration", has led to the fact that the therapist and the cardiologist do not think about the nosology of valve lesions, have no remembrance of other diseases, leading to development of a valve defect. The therapist must be able to diagnose and guide treatment for most patients with valvular heart diseases. Patients with clinically significant manifestations of valvular heart diseases (presence of complaints, appearance of specific symptoms) should always be considered as candidates for cardiac surgery. More complex decision-making may be required in cases of asymptomatic defect, with high risk surgery, old age, etc.
Texto integral
Sobre autores
Gennadiy Gendlin
N.I. Pirogov Russian national research medical universityMD, professor, Department of hospital therapy №2
Yelena Yemelina
N.I. Pirogov Russian national research medical universityPhD, assistant professor, Department of hospital therapy №2
Igor Nikitin
N.I. Pirogov Russian national research medical universityMD, professor, head of the Department of hospital therapy №2
Bibliografia
- Сторожаков Г.И., Гендлин Г.Е., Миллер О.А. Болезни клапанов сердца. М.: Практика, 2015. 200 с. [Storozhakov G.I., Gendlin G.Ye., Miller O.A. Diseases of the heart valves. Moscow: Practice, 2015. 200 p. (in Russ.)]
- Татаринова Т.Н. Роль мутаций гена notchl в развитии коарктации аорты. Северо-Западный федеральный медицинский исследовательский центр им. В.А. Алмазова. Санкт-Петербург, 2016. [Tatarinova T.N. The role of mutations in the gene notchl in the development of coarctation of the aorta. V.A. Almazov Federal North-West medical research centre. Saint Petersburg, 2016 (in Russ.)]
- Nishimura R.A., Otto C.M., Bonow R.O., Carabello B.A., Erwin J.P. 3rd, Guyton R.A., O'Gara P.T., Ruiz C.E., Skubas N.J., Sorajja P., Sundt T.M. 3rd, Thomas J.D. 2014 AHA/ACC Guideline for the management of patients with valvular heart disease: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. published online. 2014; ISSN: 1524-4539.
- Darby S., Mcgale P., Peto R., Granath F., Hall P., Ekbom A. Mortality from cardiovascular disease more than 10 years after radiotherapy for breast cancer: nationwide cohort study of 90,000 Swedish women. Br. Med. J. 2003;326:256-7.
- Clarke M., Collins R., Darby S., Davies C., Elphinstone P., Evans V., Godwin J., Gray R., Hicks C., James S., MacKinnon E., McGale P., McHugh T., Peto R., Taylor C., Wang Y.; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;366:2087-106.
- Gaya A.M., Ashford R.F. Cardiac complications of radiation therapy. Clin. Oncol. (R. Coll. Radiol.). 2005;17(3):153-9.
- Adams M.J., Lipshultz S.E., Schwartz C., Fajardo L.F., Coen V., Constine L.S. Radiation-associated cardiovascular disease: manifestations and management. Semin. Radiat. Oncol. 2003;13:346-56.
- Dale K., Coleman C., Henyan N., Kluger J., White C.M. Statins and cancer risk, a meta-analysis. JAMA. 2006;295(1):74-80.
- Schultz-Hector S., Trott K.R. Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiological data? Int. J. Radiat. Oncol. Biol. Phys. 2007; 67:10-8.
- Heidenreich P.A., Kapoor J.R. Radiation induced heart disease: systemic disorders in heart disease. Heart. 2009;95:252-8.
- Adams M.J., Lipsitz S.R., Colan S.D., Tarbell N.J., Treves S.T., Diller L., Greenbaum N., Mauch P., Lipshultz S.E. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J. Clin. Oncol. 2004;22:3139-48.
- Cutter D.J., Schaapveld M., Darby S.C., Hauptmann M., Hauptmann M., van Nimwegen F.A., Krol A.D., Janus C.P., van Leeuwen F.E., Aleman B.M. Risk for Valvular Heart Disease After Treatment for Hodgkin Lymphoma. J. Natl. Cancer Inst. 2015;107(4):1-9.
- Jurcut R., Wildiers H., Ganame J., D'hooge J., Paridaens R., Voigt J.U. Detection and monitoring of cardiotoxicity-what does modern cardiology offer? Support Care Cancer. 2008;16:437-45.
- Basavaraju S.R., Easterly C.E. Pathophysiological effects of radiation on atherosclerosis development and progression, and the incidence of cardiovascular complications. Med. Phys. 2002;29:2391-403.
Arquivos suplementares
